Ex-Astra USA Chief Charged With Fraud
Lars Bildman, who was dismissed last April as president and chiefexecutive of Astra USA amid allegations of sexual harassment and possible fraud (Marketletters passim), has now been charged with defrauding Astra of over $1 million.
According to press reports, Mr Bildman is accused of claiming his personal holidays as business expenses - which in one case included payment of prostitutes for himself and others, of filing false state and federal income tax returns for 1993-1995 and destroying Astra records in order to cover up his activities.
Also indicted, reports the Financial Times, was Astra USA's ex-chief financial officer Stefan Solvell, who left the firm last year, for failing to report income on state and federal tax returns.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze